Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys
|
|
- Joy Bridges
- 6 years ago
- Views:
Transcription
1 Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys Dan H. Barouch, 1,2, * Kathryn E. Stephenson, 1 Erica N. Borducchi, 1 Kaitlin Smith, 1 Kelly Stanley, 1 Anna G. McNally, 1 Jinyan Liu, 1 Peter Abbink, 1 Lori F. Maxfield, 1 Michael S. Seaman, 1 Anne-Sophie Dugast, 2 Galit Alter, 2 Melissa Ferguson, 3 Wenjun Li, 4 Patricia L. Earl, 5 Bernard Moss, 5 Elena E. Giorgi, 6 James J. Szinger, 6 Leigh Anne Eller, 7 Erik A. Billings, 7 Mangala Rao, 7 Sodsai Tovanabutra, 7 Eric Sanders-Buell, 7 Mo Weijtens, 8 Maria G. Pau, 8 Hanneke Schuitemaker, 8 Merlin L. Robb, 7 Jerome H. Kim, 7 Bette T. Korber, 6 and Nelson L. Michael 7 1 Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA 2 Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard, Boston, MA 02114, USA 3 Alpha Genesis, Inc., Yemassee, SC 29945, USA 4 University of Massachusetts Medical School, Worcester, MA 01605, USA 5 National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA 6 Los Alamos National Laboratory, Los Alamos, NM 87545, USA 7 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, MD 20850, USA 8 Crucell Holland BV, 2301 CA Leiden, the Netherlands *Correspondence: dbarouch@bidmc.harvard.edu SUMMARY The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed for improved coverage of HIV-1 diversity. However, the protective efficacy of such global HIV-1 vaccine antigens has not previously been evaluated. Here, we demonstrate the capacity of bivalent HIV-1 mosaic antigens to protect rhesus monkeys against acquisition of infection following heterologous challenges with the difficult-to-neutralize simian-human immunodeficiency virus SHIV- SF162P3. Adenovirus/poxvirus and adenovirus/ adenovirus vector-based vaccines expressing HIV-1 mosaic Env, Gag, and Pol afforded a significant reduction in the per-exposure acquisition risk following repetitive, intrarectal SHIV-SF162P3 challenges. Protection against acquisition of infection correlated with vaccine-elicited binding, neutralizing, and functional nonneutralizing antibodies, suggesting that the coordinated activity of multiple antibody functions may contribute to protection against difficult-to-neutralize viruses. These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. INTRODUCTION The extraordinary degree of HIV-1 sequence diversity worldwide represents one of the most daunting challenges for the development of a global HIV-1 vaccine (Barouch, 2008; Gaschen et al., 2002; Walker and Korber, 2001). The development of a vaccine that is immunologically relevant for multiple regions of the world is therefore a key research priority (Stephenson and Barouch, 2013). One possible solution would be to develop a different HIV-1 vaccine for each geographic region that is tailored to local circulating isolates. However, a single global vaccine would offer important biomedical and practical advantages over multiple regional clade-specific vaccines. Mosaic antigens (Fischer et al., 2007) and conserved antigens (Létourneau et al., 2007; Stephenson et al., 2012b) represent two potential strategies to address the challenges of global HIV-1 diversity. Mosaic antigens aim to elicit increased breadth of humoral and cellular immune responses for improved immunologic coverage of diverse sequences, whereas conserved antigens aim to focus cellular immune responses on regions of greatest sequence conservation. Immunogenicity studies in nonhuman primates have shown that mosaic antigens elicit increased cellular immune breadth and depth (Barouch et al., 2010; Santra et al., 2010), as well as augmented antibody responses (Barouch et al., 2010; Stephenson et al., 2012b), as compared with natural sequence and consensus antigens. However, no previous studies have assessed the protective efficacy of these global HIV-1 antigen concepts, and it has been unclear whether the immune responses elicited by in silico derived synthetic antigens will exert biologically relevant antiviral activity. This question is of particular importance given the current plans for clinical development of these mosaic antigens. It has also proven challenging to evaluate the preclinical efficacy of HIV-1 immunogens that do not have SIV homologs. This is relevant for HIV-1 mosaic antigens because HIV-1 sequence diversity in humans is biologically substantially different from SIV sequence diversity in sooty mangabees. Moreover, SIV in natural hosts exhibits markedly decreased Cell 155, , October 24, 2013 ª2013 Elsevier Inc. 531
2 positive selection as compared with HIV-1 in humans, presumably as a result of the lower level of immune selection pressure and a much longer evolutionary history (Fischer et al., 2012). In addition, only limited numbers of SIV sequences are available to inform mosaic vaccine design (Fischer et al., 2012). It is currently not possible to develop SIV homologs of mosaic antigens that accurately recapitulate the biology of HIV-1 mosaic antigens, and we therefore opted not to assess the protective efficacy of SIV homologs of mosaic antigens in SIV challenge models. Instead, we evaluated the capacity of HIV-1 mosaic antigens to protect against stringent simian-human immunodeficiency virus (SHIV) challenges in rhesus monkeys. In this study, we assessed the immunogenicity of bivalent HIV-1 mosaic Env/Gag/Pol immunogens (Barouch et al., 2010) delivered by optimized Ad/MVA or Ad/Ad prime-boost vector regimens (Barouch et al., 2012), and we evaluated the protective efficacy of these vaccines against repetitive, intrarectal challenges with the stringent, difficult-to-neutralize, heterologous virus SHIV-SF162P3 in rhesus monkeys. Because SHIVs incorporate HIV-1 Env and SIV Gag/Pol (Reimann et al., 1996a, 1996b), this study primarily evaluated the ability of the HIV-1 Env components of these vaccines to block acquisition of infection. To the best of our knowledge, this study represents the first evaluation of the protective efficacy of a candidate global HIV-1 antigen strategy in nonhuman primates. We demonstrate that binding, neutralizing, and nonneutralizing antibody responses correlate with protection, suggesting that the coordinated activity of multiple antibody functions may contribute to protective efficacy. RESULTS Evaluation of a Global HIV-1 Mosaic Vaccine in Rhesus Monkeys We immunized 36 Indian-origin rhesus monkeys (Macaca mulatta) that did not express the class I alleles associated with spontaneous virologic control (Mamu-A*01, Mamu-B*08, and Mamu-B*17) (Loffredo et al., 2007; Mothé et al., 2003; Yant et al., 2006) with Ad prime, MVA boost (Group 1; n = 12) or Ad prime, Ad boost (Group 2; n = 12) vector regimens expressing bivalent M mosaic Env/Gag/Pol immunogens or with sham vaccines (Group 3; n = 12). In Group 1, half the animals received the Ad26 prime, MVA boost regimen, and half received the Ad35 prime, MVA boost regimen. In Group 2, half the animals received the Ad26 prime, Ad35 boost regimen, and half received the Ad35 prime, Ad26 boost regimen. One animal in Group 1 died for reasons unrelated to the study prior to the boost immunization and thus was excluded from the analysis. Groups were balanced for animals with susceptible and resistant TRIM5a alleles (Letvin et al., 2011; Lim et al., 2010). The Ad vectors expressing HIV-1 mosaic Env/Gag/Pol have been described previously (Barouch et al., 2010). The MVA vectors were constructed by inserting the HIV-1 mosaic Env and Gag/Pol expression cassettes into two distinct regions of the MVA backbone (Earl et al., 2004) (L.A.E., P.L.E., and B.M., unpublished data). At week 0, monkeys were primed by the intramuscular (i.m.) route with a total dose of viral particles (vp) Ad26 or Ad35 vectors. At week 12, animals were boosted i.m. with vp Ad26 or Ad35 vectors or 10 8 pfu MVA vectors. Binding, Neutralizing, and Nonneutralizing Antibody Responses Binding antibody responses were detected in all vaccinated animals by ELISA (Nkolola et al., 2010) at week 4 after the priming immunization and increased substantially following the boost immunization (Figure 1A). Binding antibodies with mean log titers of were detected at week 16 against diverse Envs from multiple clades (Barouch et al., 2010) (92UG037, UG92/29, CN54, ZA/97/003, 92UG021, 93BR029), as well as against one of the homologous mosaic Envs (Mos1) included in the vaccine. Antibody titers declined 1 to 2 logs from peak to mean log titers of by week 32, and titers were then stable through week 52 (data not shown). Antibody responses against the Env V2 loop (Haynes et al., 2012) were also detected against multiple clades (92TH023, B_MN, ConC, Mos1, Mos2) using surface plasmon resonance assays with cyclic peptides (Figure 1B) and gp70- V1V2 fusion proteins (data not shown). No significant immunologic differences were observed among the different vector regimens. Neutralizing antibodies (NAbs) against easy-to-neutralize tier 1 viruses were detected by TZM-bl virus neutralization assays (Montefiori, 2004). Mean titers of were detected at week 16 against SF162 (clade B) and MW965 (clade C), and low mean titers of were observed against DJ263 (clade A) (Figure 1C). Low but clear mean titers of were also detected against 3 of 4 difficult-to-neutralize tier 2 viruses by A3R5 assays, including SC22 (clade B), 1086 (clade C), and DU422 (clade C) (Figure 1D). Moreover, low NAb titers were observed against the difficult-to-neutralize tier 2 SHIV- SF162P3 challenge virus by TZM-bl assays (Figure 1E). Nonneutralizing functional antibody-dependent complement deposition (ADCD) (Figure 1F) and antibody-dependent cellular phagocytosis (ADCP) (Figure 1G) (Ackerman et al., 2011) responses were also observed at week 16. ADCD assays evaluated antibody-mediated C3b deposition on Env-pulsed CEM target cells, and ADCP assays assessed antibody-mediated phagocytosis of Env-pulsed fluorescent beads by THP-1 cells. Low levels of antibody-dependent cellular cytotoxicity (ADCC) were also detected (data not shown) (Gómez-Román et al., 2006). These data demonstrate that the Ad/MVA and Ad/Ad regimens expressing the mosaic Env immunogens elicited a diversity of binding, neutralizing, and nonneutralizing antibody responses. Breadth and Depth of Cellular Immune Responses Robust cellular immune responses against HIV-1 Env, Gag, and Pol were detected by IFN-g ELISPOT assays (Liu et al., 2009). The magnitude and breadth of cellular immune responses (Figures 2A and 2B) were comparable for the various vector regimens tested and were similar to our previously reported findings (Barouch et al., 2010; Stephenson et al., 2012b). Detailed epitope mapping was performed using both homologous mosaic and heterologous global potential T cell epitope (PTE) peptides, and the minimal number of epitope-specific responses was determined for each animal (Table S1 available online). There were significantly more CD8+ than CD4+ T lymphocyte responses per animal (p = , Wilcoxon rank-sum test) (Figures 2C and 2D). Most epitope-specific responses were 532 Cell 155, , October 24, 2013 ª2013 Elsevier Inc.
3 Figure 1. Vaccine-Elicited Humoral Immune Responses (A) Env-specific ELISAs using a diversity of Envs from multiple clades, including 92UG037 (UG37; clade A), UG92/29 (UG92; clade A), CN54 (clade C), ZA/97/003 (ZA97; clade C), 92UG021 (UG21; clade D), 93BR029 (BR29; clade F), and mosaic (Mos1; clade M) at weeks 0, 4, 16, and 32. Mean log endpoint ELISA titers ± SEM are shown. (B) V2-specific binding assays by surface plasmon resonance using cyclic V2 peptides from multiple clades, including 92TH023 (TH23; clade AE), MN (clade B), ConC (clade C), Mos1 (clade M), and Mos2 (clade M) at weeks 0, 4, 16, and 24. V2-specific binding assays were not run with the TH23 and MN cyclic V2 peptides at week 24. Mean response units ± SEM are shown. (C) HIV-1 tier 1 TZM-bl neutralization assays against DJ263 (clade A), SF162 (clade B), and MW965 (clade C) at weeks 0, 4, 16, and 32. Mean ID50 titers ± SEM are shown. (D) HIV-1 tier 2 A3R5 neutralization assays against SC22 (clade B), 1086 (clade C), and DU422 (clade C) at weeks 0 and 16. Mean ID50 titers ± SEM are shown. (E) HIV-1 tier 2 TZM-bl neutralization assays against the SHIV-SF162P3 challenge stock at weeks 0, 16, and 32. Mean ID50 titers are shown. (F) ADCD assays with YU2 (clade B) and SF162 (clade B) Env gp120. Mean % C3b deposition responses ± SEM are shown. (G) ADCP assays with SF162 (clade B) Env gp120. Mean phagocytic score responses ± SEM are shown. Cell 155, , October 24, 2013 ª2013 Elsevier Inc. 533
4 Figure 2. Vaccine-Elicited Cellular Immune Responses (A) IFN-g ELISPOT assays using global PTE peptide pools at weeks 0, 4, and 16. Mean spot-forming cells (SFC) per 10 6 PBMC ± SEM are shown. (B) Numbers of reactive subpools of peptides using PTE and mosaic peptide sets. Mean subpools ± SEM are shown. (C) Numbers of mapped individual CD8+ and CD4+ T lymphocyte epitopes. Mean epitopes ± SEM are shown. (D) Individual CD8+ and CD4+ epitope-specific immune responses mapped with heterologous PTE and vaccine-matched mosaic peptide sets. 83 responses were detected by both PTE and mosaic peptides, 58 by only mosaic peptides, and 27 by only PTE peptides. Box-and-whisker plots are shown. See also Figure S1, Table S1, and Data S2. detected using both peptide sets, but certain epitopes were detected uniquely with either the mosaic peptides or the PTE peptides (Figure 2D). Individual epitope-specific CD8+ and CD4+ T lymphocyte responses showed substantial animal-toanimal variability (Figure S1) but nevertheless appeared to cluster in immunologic hot spots (Data S1), despite the outbred nature of the monkeys. Protective Efficacy, Immunologic Correlates of Protection, and Clinical Disease To assess the protective efficacy of the vaccines, we challenged all animals beginning at week 52 (9 months following the boost immunization) 6 times with a 1:100 dilution of our SHIV- SF162P3 challenge stock (GenBank KF042063; Data S2). The SHIV-SF162P3 Env had 13% amino acid sequence differences compared with Mos1 Env from the vaccine and 26% amino acid sequence differences compared with Mos2 Env. After the first challenge, 8 of 11 (73%) Ad/MVA and 8 of 12 (67%) Ad/Ad vaccinated animals remained uninfected as compared with only 2 of 12 (17%) controls (Figures 3A and 3B; p = 0.03, Fisher s exact test). After the third challenge, 5 of 11 (45%) Ad/MVA and 5 of 12 (42%) Ad/Ad vaccinated animals remained uninfected as compared with 0 of 12 (0%) controls (Figures 3A and 3B; p = 0.03, Fisher s exact test). As expected, absolute protection declined with additional challenges, and after the sixth and final challenge, only 2 of 11 (18%) Ad/MVA and 1 of 12 (8%) Ad/Ad vaccinated animals remained uninfected. These data reflected a 90% (p = 0.002, Cox proportional hazard model using the number of challenges as a discrete time scale) and 87% (p = 0.007) reduction, respectively, in the per-exposure relative risk of acquisition of infection (Figures 3A and 3B) (Hudgens and Gilbert, 2009; Hudgens et al., 2009). Thus, the mosaic HIV-1 vaccines afforded partial protection against acquisition of infection following repetitive, intrarectal, heterologous SHIV-SF162P3 challenges. No differences in protective efficacy were observed between Ad26 versus Ad35 priming in each group (data not shown). We next evaluated the immunologic correlates of protection against acquisition of infection in the vaccinated animals, defined as the number of challenges required for infection. We assessed 47 humoral and cellular immunologic parameters for potential correlation with protection (Table S2). Three 534 Cell 155, , October 24, 2013 ª2013 Elsevier Inc.
5 Figure 3. Protective Efficacy against SHIV- SF162P3 Challenges (A) Number of challenges required for acquisition of infection in each vaccine group. (B) Statistical analyses include hazard ratios with 95% confidence intervals (CI), the per-exposure reduction in acquisition risk, and the absolute percentage of uninfected animals in each group after 1, 3, and 6 challenges. p values reflect Cox proportional hazard model. (C) Log peak SIV RNA copies/ml are depicted for each group. p values represent Wilcoxon ranksum tests. Box-and-whisker plots are shown. (D) Log set point SIV RNA copies/ml are depicted for each group at day 70. Box-and-whisker plots are shown. (E) Clinical survival curve. (F) Statistical analyses of survival at 250 days following challenge. p values reflect Fisher s exact tests comparing the vaccinated groups to the control group. parameters were significantly associated with protection after Bonferroni multiple comparison adjustments. Protection was most strongly correlated with week 16 ELISA binding antibody titers against the homologous Mos1 Env immunogen (p = , Spearman rank-correlation test; Figure 4A). Protection was also correlated with ELISA binding antibody titers against other Env immunogens, although these associations were less robust (Table S2 and Figure S2). In addition, protection was significantly correlated with NAb titers against SF162 (p = ; Figure 4B), which is a neutralization-sensitive virus that is related to the challenge virus SHIV-SF162P3. NAb titers against other tier 1 viruses also showed trends toward correlation with protection (Table S2 and Figure S3). In addition, protection was correlated with functional nonneutralizing ADCP phagocytic score (p = ; Figure 4C), and a trend was observed with ADCD C3b complement deposition (Figure 4D). We did not, however, observe significant correlations of protection with surface plasmon resonance binding to cyclic V2 peptides or gp70-v1v2 fusion proteins or any measure of CD8+ T lymphocyte responses. Peak viral loads were modestly lower in the vaccinated animals as compared with the controls. Median peak viral loads in the Ad/MVA and Ad/Ad vaccinated monkeys were 0.50 (p = 0.048, Wilcoxon rank-sum test) and 0.55 (p = 0.017) logs lower, respectively, than in the controls (Figure 3C). Set point viral loads trended 1.14 and 0.55 logs lower in the vaccine groups, respectively, than in the controls (Figure 3D). The HIV-1 mosaic Gag and Pol immunogens in the vaccine had no detectable immunologic cross-reactivity with SIVmac239 Gag and Pol in the challenge virus by pooled peptide IFN-g ELISPOT assays (data not shown). Thus, the modest virologic control likely reflected Env-specific immune responses, although the magnitude and breadth of Env-specific T lymphocyte responses were not significantly correlated with virologic control (Table S2). This is consistent with our previous observations that virologic control following challenge is primarily mediated by Gag-specific cellular immune responses (Stephenson et al., 2012a), and thus it is not surprising that the observed virologic control was only modest in this study. In contrast, similar Ad/MVA and Ad/Ad vector regimens expressing SIVsmE543 antigens afforded >2 log reductions of set point viral loads following heterologous SIVmac251 challenges in a prior study (Barouch et al., 2012). We observed substantial clinical disease progression and AIDS-related mortality in the controls. At 250 days following challenge, all of the vaccinated animals survived, as compared with only 7 of 12 (58%) of controls (Figures 3E and 3F; p = 0.03, Fisher s exact test). These data confirm the stringency of our SHIV-SF162P3 challenge stock and demonstrate a survival advantage of the HIV-1 mosaic vaccines in this model. Cell 155, , October 24, 2013 ª2013 Elsevier Inc. 535
6 Figure 4. Immunologic Correlates of Protection (A) Correlation of log Mos1 ELISA titers at peak immunogenicity with the number of challenges required to establish infection. (B) Correlation of log SF162 NAb titers at peak immunogenicity with the number of challenges required to establish infection. (C) Correlation of SF162 ADCP phagocytic score at peak immunogenicity with the number of challenges required to establish infection. (D) Correlation of SF162 ADCD % C3b deposition at peak immunogenicity with the number of challenges required to establish infection. For all panels, correlates analyses included only the vaccinated monkeys that became infected and did not include the sham controls. p values reflect uncorrected Spearman rank-correlation tests. See also Figures S2 and S3 and Table S2. DISCUSSION This study demonstrates the protective efficacy of a global HIV-1 vaccine candidate in nonhuman primates. In particular, bivalent mosaic HIV-1 Env/Gag/Pol delivered by Ad/MVA or Ad/Ad vector regimens afforded substantial partial protection against repetitive, intrarectal, heterologous SHIV-SF162P3 challenges in rhesus monkeys. Although most vaccinated animals became infected by the end of the challenge series, we observed 87% 90% reduction in the per-exposure probability of infection. This protective effect was likely mediated by Env-specific immune responses because the challenge virus contained SIVmac239 Gag/Pol. These findings suggest that HIV-1 mosaic vaccine candidates should be evaluated in clinical trials. The majority of HIV-1 vaccine candidates have to date only demonstrated protective efficacy against low stringency, easy-to-neutralize virus challenges. For example, DNA/Ad5 vaccines afforded partial protection against acquisition of the easy-to-neutralize virus SIVsmE660 but failed to protect against the difficult-to-neutralize virus SIVmac251 (Letvin et al., 2011). Moreover, HIV-1 Env vaccines have typically only been tested for protective efficacy against easy-to-neutralize viruses, such as SHIV-SF162P4 or SHIV-BaL (Barnett et al., 2008, 2010), rather than against the difficult-to-neutralize virus SHIV- SF162P3. The recent failure of the DNA/Ad5 vaccine in humans suggests that preclinical evaluations of HIV-1 vaccine candidates should involve difficult-to-neutralize challenge models with higher stringency. The protection observed in the present study is therefore notable in that SHIV-SF162P3 exhibits a tier 2 difficult-to-neutralize phenotype that is typical of a primary virus isolate (Seaman et al., 2010). Moreover, SHIV-SF162P3 resulted in moderate to high viral loads and substantial clinical disease progression and AIDS-related mortality in the controls (Figure 3). Importance of Vaccine-Elicited Antibody Responses Consistent with previous data in the SIVmac251 challenge model (Barouch et al., 2012), we observed that Env-specific binding antibodies correlated most strongly with protection. Binding antibodies were detected as immune correlates in the RV144 clinical vaccine trial (Haynes et al., 2012; Rerks-Ngarm et al., 2009), although we did not detect V2-specific correlates for protection in the present study, perhaps reflecting different vaccine vectors, challenge viruses, or V2 scaffolds utilized in the immunologic assays. Vaccine-elicited NAbs against SF162 also correlated with protection, and low levels of NAbs were detected against the heterologous, difficult-to-neutralize SHIV-SF162P3 challenge virus. In addition, nonneutralizing ADCP responses also correlated with protection. These data demonstrate that immunologic correlates of protection were complex and involved multiple vaccine-elicited binding, neutralizing, and nonneutralizing antibody responses. It is therefore possible, in the absence of high titers of broadly neutralizing antibodies, that the coordinated activity of multiple antibody functions may contribute to affording protection against difficult-to-neutralize viruses. The mosaic Env immunogens also elicited broad Env-specific CD4+ T lymphocyte responses that may have facilitated the induction and durability of antibody responses. Implications for HIV-1 Vaccine Development Mosaic antigens represent a potential strategy to improve humoral and cellular immunologic coverage of global HIV-1 diversity as compared with conventional natural sequence antigens, and they are therefore promising for HIV-1 vaccine development. Mosaic antigens may also offer a practical strategy for achieving comparable immunologic coverage utilizing fewer vaccine antigens than would be required with cocktails of natural sequence antigens. Clinical evaluation of the bivalent HIV-1 mosaic antigens in humans is therefore planned. The present findings demonstrate that the immune responses elicited by these synthetic antigens can afford protection in vivo. 536 Cell 155, , October 24, 2013 ª2013 Elsevier Inc.
7 Moreover, the correlation of multiple antibody parameters with protection suggests that both neutralizing and nonneutralizing antibodies may contribute to protection. A limitation of the present study, however, is that we were only able to evaluate protective efficacy against a single clade B challenge virus. Ideally, global HIV-1 antigens should be assessed for protective efficacy against a panel of diverse SHIVs. However, SHIV challenge stocks from multiple clades do not yet exist, with the exception of a limited number of clade C SHIVs (Ren et al., 2013; Siddappa et al., 2010, 2011). Thus, future studies could evaluate the protective efficacy of global HIV-1 mosaic antigens against a diversity of virus isolates after additional SHIV challenge stocks are developed. The clinical implications of our data remain unknown and will require efficacy trials in humans. However, it is worth noting that the viral challenge in the present study was 100-fold more infectious than typical sexual HIV-1 exposures in humans. Moreover, future studies are planned utilizing purified recombinant Env trimers to boost the antibody responses elicited by these HIV-1 mosaic vector regimens. In summary, this study demonstrates the initial proof-of-concept protective efficacy of synthetic HIV-1 mosaic antigens in rhesus monkeys and provides important insights into the correlates of protection against stringent virus challenges. EXPERIMENTAL PROCEDURES Animals, Immunizations, and Challenges 36 Indian-origin, outbred, young adult, male and female, specific pathogen-free (SPF) rhesus monkeys (Macaca mulatta) that did not express the class I alleles Mamu-A*01, Mamu-B*08, and Mamu-B*17 associated with spontaneous virologic control (Loffredo et al., 2007; Mothé et al., 2003; Yant et al., 2006) were utilized for this study. Groups were balanced for susceptible and resistant TRIM5a alleles (see also Table S3) (Letvin et al., 2011; Lim et al., 2010). Immunizations were performed by the i.m. route in the quadriceps muscles with vp Ad35 vectors (Vogels et al., 2003), vp Ad26 vectors (Abbink et al., 2007), or 10 8 pfu MVA vectors expressing bivalent M mosaic Env/Gag/Pol antigens (Barouch et al., 2010). Monkeys were primed at week 0 and boosted at week 12. To evaluate for protective efficacy, all monkeys were challenged repetitively beginning at week 52 with six intrarectal inoculations of the heterologous virus SHIV-SF162P3 utilizing a 1:100 dilution of our challenge stock. This virus stock was produced by expansion of the NIAID SHIV-SF162P3 stock in rhesus peripheral blood mononuclear cells (PBMC) followed by titration by the intrarectal route in rhesus monkeys and full genome sequencing (see also Data S2). Following challenge, monkeys were bled weekly for viral loads (Siemans Diagnostics), and the date of infection was defined as the last challenge time point prior to the first positive SIV RNA level. Animals were followed to determine set point viral loads. All animal studies were approved by the appropriate Institutional Animal Care and Use Committee (IACUC). Humoral Immune Assays ELISA HIV-1-specific humoral immune responses were assessed by Env ELISAs (Nkolola et al., 2010) using antigens produced in stably transfected 293 cells or commercially purchased (Polymun). V2 binding assays were performed by surface plasmon resonance with a Biacore T100 or T200 using a 1:50 serum dilution and cyclic V2 peptides containing an N-terminal biotin tag and immobilized on streptavidin-coated CM5 chips (Barouch et al., 2012) or using gp70- V1V2 fusion proteins. NAb Assays TZM-bl luciferase-based virus neutralization assays (Montefiori, 2004) were performed with tier 1 viruses and the tier 2 SHIV-SF162P3 challenge stock. A3R5 virus neutralization assays were conducted with tier 2 viruses. ADCP Functional nonneutralizing antibody responses utilized IgG purified from serum using Melon Gel columns (Thermo Scientific) and quantitated using a Nanodrop spectrophotometer (Thermo Scientific). ADCP assays were performed as previously described (Ackerman et al., 2011). SF162 gp120 biotinylated antigen was incubated with 1 mm yellow-green fluorescent neutravidin beads (Invitrogen) overnight. The beads were then washed and resuspended at a final dilution of 1:100 in PBS-BSA. Antibodies and antigen-labeled beads were mixed in a round-bottom 96-well plate, and the plate was incubated for 2 hr. THP-1 cells ( cells) were then added to each well in a final volume of 200 ml, and the plate was incubated overnight. The next day, half the culture volume was removed and replaced with 100 ml of 4% paraformaldehyde before the plates were analyzed on a BD LSR II equipped with an HTS plate reader. For analysis, the samples were gated on live cells, and the proportion of THP-1 cells phagocytosing beads was determined. A phagocytic score was calculated as follows: % bead positive 3 MFI bead positive. Rapid Fluorometric ADCC The rapid fluorometric ADCC (RF-ADCC) assay was performed as previously described (Gómez-Román et al., 2006). Briefly, CEM.NKr cells (AIDS Reagent Program) were pulsed with 6 mg of recombinant SF162 gp120 for 1 hr and then washed twice in cold media. Uncoated CEM.NKr cells were used as a negative control. Both the coated and uncoated target cells were stained with 1.5 mm PKH26 (Sigma) and 100 nm 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE). After staining, the cells were resuspended at a concentration of cells/ml, and cells were added to each well. Purified antibodies were added (50 mg/ml), and the plates were incubated for 20 min at 37 C and 5% CO 2 to allow the binding of the antibodies to the target cell. Natural killer (NK) cells were isolated directly from healthy donor whole blood by negative selection using RosetteSep (Stem Cell Technologies) and added to each well at an effector:target ratio 10:1. The plates were then incubated for 4 hr at 37 C, after which the cells were fixed in 2% paraformaldehyde. ADCC activity was determined using flow cytometry and was based on the loss of CFSE on PKH + CEM.NKr cells. The data were analyzed using FlowJo software, and the percentage of CFSE loss within the PKH + CEM.NKr population was determined. ADCD ADCD was determined by C3b deposition on gp120-pulsed target cells. Briefly, CEM.NKr cells were pulsed with 6 mg of recombinant gp120 (YU-2 or SF162) for 1 hr at room temperature and then washed twice in cold media. Uncoated CEM.NKr cells were used as a negative control. Plasma was utilized as a source of complement for the assay. 25 mg purified antibodies were added to 10 5 CEM.NKr cells in the presence of plasma diluted 1:10 in veronal buffer supplemented with 0.1% gelatin for 20 min at 37. Cells were washed and stained with a FITC-conjugated C3b antibody for 15 min, washed, and fixed in 4% PFA. HIVIG was used a positive control for this assay, and heat-inactivated plasma and antibodies from naive controls were utilized as negative controls. Cellular Immune Assays HIV-1-specific cellular immune responses were assessed by IFN-g ELISPOT assays as previously described (Liu et al., 2009). ELISPOT assays utilized pools of HIV-1 PTE or mosaic peptides. Analyses of cellular immune breadth utilized subpools of peptides covering each antigen followed by epitope mapping using individual peptides, essentially as we have previously reported (Barouch et al., 2010). Epitope-specific CD8+ and CD4+ T lymphocyte responses were determined by cell depletion studies. Statistical Analyses and Immunologic Correlates Protection against acquisition of infection was analyzed using Cox proportional hazard models based on the exact partial likelihood for discrete time. The number of challenges was used as a discrete time scale. The hazard ratios with 95% confidence intervals (CI) for the per-exposure relative reductions of acquisition risk were calculated for the Ad/MVA and Ad/Ad groups as compared to the control group (Hudgens and Gilbert, 2009; Hudgens et al., 2009). Absolute protection against acquisition of infection after 1, 3, and 6 challenges was quantitated as the percentage of uninfected animals as Cell 155, , October 24, 2013 ª2013 Elsevier Inc. 537
8 compared to the control group. Mortality at 250 days following challenge in the vaccine groups was compared to the control group by Fisher s exact tests. Analyses of virologic and immunologic data were performed using Wilcoxon rank-sum tests. For these tests, p < 0.05 was considered significant. Immunologic correlates were evaluated by Spearman rank-correlation tests, and p < was considered significant to adjust for multiple (47) comparisons. ACCESSION NUMBERS The GenBank accession number for the challenge virus sequence reported in this paper is KF SUPPLEMENTAL INFORMATION Supplemental Information includes three figures, two data files, and three tables and can be found with this article online at AUTHOR CONTRIBUTIONS D.H.B., M.G.P., H.S., M.L.R., J.H.K., B.T.K., and N.L.M. designed the study and interpreted data. K.E.S., E.N.B., K.S., and A.G.M. performed the cellular immunogenicity assays. K.S., M.S., A.-S.D., G.A., E.A.B., and M.R. performed the humoral immunogenicity assays. P.A., L.F.M., P.L.E., B.M., L.A.E., M.W., and M.G.P. prepared the vaccine constructs. J.L., S.T., E.S., and J.H.K. prepared and sequenced the challenge virus. M.F. led the clinical care of the rhesus monkeys. W.L., E.E.G., J.J.S., and B.T.K. performed the data and statistical analyses. D.H.B. led the study and wrote the paper with all co-authors. ACKNOWLEDGMENTS We thank M. Pensiero, S. Blackmore, R. Bradsky, C. Cabral, A. Cheung, J. Goudsmit, R. Hamel, B. Hibl, S. Howell, M. Iampietro, K. Kelly, D. Lynch, M. Marovich, C. Miller, J. Nkolola, A. O Sullivan, L. Parenteau, J. Perry, W. Rinaldi, J. Sadoff, A. SanMiguel, N. Simmons, J. Smith, F. Stephens, D. van Manen, G. Westergaard, and L. Wyatt for generous advice, assistance, and reagents. The HIV-1 PTE peptides were obtained from the NIH AIDS Research and Reference Reagent Program. We acknowledge support from the U.S. Military Research and Material Command and the U.S. Military HIV Research Program (W81XWH ); the National Institutes of Health (AI052074, AI060354, AI078526, AI084794, AI095985, AI096040, and AI100645); the NIAID Division of Intramural Research; the Ragon Institute of MGH, MIT, and Harvard; and the Bill and Melinda Gates Foundation (OPP and OPP ). M.W., M.G.P., and H.S. are employees of Crucell. Beth Israel Deaconess Medical Center and Los Alamos National Laboratory are co-owners of an HIV-1 mosaic antigen patent that has been licensed to Crucell. The opinions in this manuscript are those of the authors and do not reflect the views of the U.S. Department of the Army or the Department of Defense. Received: June 27, 2013 Revised: September 5, 2013 Accepted: September 27, 2013 Published: October 24, 2013 REFERENCES Abbink, P., Lemckert, A.A., Ewald, B.A., Lynch, D.M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A.R., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, Ackerman, M.E., Moldt, B., Wyatt, R.T., Dugast, A.S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C.T., Sciaranghella, G., Liu, Q., et al. (2011). A robust, highthroughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, Barnett, S.W., Srivastava, I.K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A.D., Ferrai, M.G., Weiss, D.E., Letvin, N.L., Montefiori, D., et al. (2008). Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22, Barnett, S.W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., Zur Megede, J., et al. (2010). Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84, Barouch, D.H. (2008). Challenges in the development of an HIV-1 vaccine. Nature 455, Barouch, D.H., O Brien, K.L., Simmons, N.L., King, S.L., Abbink, P., Maxfield, L.F., Sun, Y.H., La Porte, A., Riggs, A.M., Lynch, D.M., et al. (2010). Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16, Barouch, D.H., Liu, J., Li, H., Maxfield, L.F., Abbink, P., Lynch, D.M., Iampietro, M.J., SanMiguel, A., Seaman, M.S., Ferrari, G., et al. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, Earl, P.L., Americo, J.L., Wyatt, L.S., Eller, L.A., Whitbeck, J.C., Cohen, G.H., Eisenberg, R.J., Hartmann, C.J., Jackson, D.L., Kulesh, D.A., et al. (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C., Haynes, B., Letvin, N.L., Walker, B.D., et al. (2007). Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, Fischer, W., Apetrei, C., Santiago, M.L., Li, Y., Gautam, R., Pandrea, I., Shaw, G.M., Hahn, B.H., Letvin, N.L., Nabel, G.J., and Korber, B.T. (2012). Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J. Virol. 86, Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B.H., Bhattacharya, T., and Korber, B. (2002). Diversity considerations in HIV-1 vaccine selection. Science 296, Gómez-Román, V.R., Florese, R.H., Patterson, L.J., Peng, B., Venzon, D., Aldrich, K., and Robert-Guroff, M. (2006). A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308, Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M., Evans, D.T., Montefiori, D.C., Karnasuta, C., Sutthent, R., et al. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, Hudgens, M.G., and Gilbert, P.B. (2009). Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 65, Hudgens, M.G., Gilbert, P.B., Mascola, J.R., Wu, C.D., Barouch, D.H., and Self, S.G. (2009). Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis. 200, Létourneau, S., Im, E.J., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L., Dong, T., Korber, B., McMichael, A.J., and Hanke, T. (2007). Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2, e984. Letvin, N.L., Rao, S.S., Montefiori, D.C., Seaman, M.S., Sun, Y., Lim, S.Y., Yeh, W.W., Asmal, M., Gelman, R.S., Shen, L., et al. (2011). Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci. Transl. Med. 3, 81ra36. Lim, S.Y., Rogers, T., Chan, T., Whitney, J.B., Kim, J., Sodroski, J., and Letvin, N.L. (2010). TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog. 6, e Liu, J., O Brien, K.L., Lynch, D.M., Simmons, N.L., La Porte, A., Riggs, A.M., Abbink, P., Coffey, R.T., Grandpre, L.E., Seaman, M.S., et al. (2009). Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, Loffredo, J.T., Maxwell, J., Qi, Y., Glidden, C.E., Borchardt, G.J., Soma, T., Bean, A.T., Beal, D.R., Wilson, N.A., Rehrauer, W.M., et al. (2007). Mamu- B*08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81, Cell 155, , October 24, 2013 ª2013 Elsevier Inc.
9 Montefiori, D.C. (2004). Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protoc. Immunol. 64, Mothé, B.R., Weinfurter, J., Wang, C., Rehrauer, W., Wilson, N., Allen, T.M., Allison, D.B., and Watkins, D.I. (2003). Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 77, Nkolola, J.P., Peng, H., Settembre, E.C., Freeman, M., Grandpre, L.E., Devoy, C., Lynch, D.M., La Porte, A., Simmons, N.L., Bradley, R., et al. (2010). Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 84, Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.W., Karlsson, G.B., Sodroski, J., and Letvin, N.L. (1996a). A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, Reimann, K.A., Li, J.T., Voss, G., Lekutis, C., Tenner-Racz, K., Racz, P., Lin, W., Montefiori, D.C., Lee-Parritz, D.E., Lu, Y., et al. (1996b). An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70, Ren, W., Mumbauer, A., Gettie, A., Seaman, M.S., Russell-Lodrigue, K., Blanchard, J., Westmoreland, S., and Cheng-Mayer, C. (2013). Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques. J. Virol. 87, Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al.; MOPH- TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, Santra, S., Liao, H.X., Zhang, R., Muldoon, M., Watson, S., Fischer, W., Theiler, J., Szinger, J., Balachandran, H., Buzby, A., et al. (2010). Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16, Seaman, M.S., Janes, H., Hawkins, N., Grandpre, L.E., Devoy, C., Giri, A., Coffey, R.T., Harris, L., Wood, B., Daniels, M.G., et al. (2010). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, Siddappa, N.B., Watkins, J.D., Wassermann, K.J., Song, R., Wang, W., Kramer, V.G., Lakhashe, S., Santosuosso, M., Poznansky, M.C., Novembre, F.J., et al. (2010). R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS ONE 5, e Siddappa, N.B., Hemashettar, G., Wong, Y.L., Lakhashe, S., Rasmussen, R.A., Watkins, J.D., Novembre, F.J., Villinger, F., Else, J.G., Montefiori, D.C., and Ruprecht, R.M. (2011). Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. J. Med. Primatol. 40, Stephenson, K.E., and Barouch, D.H. (2013). A global approach to HIV-1 vaccine development. Immunol. Rev. 254, Stephenson, K.E., Li, H., Walker, B.D., Michael, N.L., and Barouch, D.H. (2012a). Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J. Virol. 86, Stephenson, K.E., SanMiguel, A., Simmons, N.L., Smith, K., Lewis, M.G., Szinger, J.J., Korber, B., and Barouch, D.H. (2012b). Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-regiononly HIV-1 immunogens in rhesus monkeys. J. Virol. 86, Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, Walker, B.D., and Korber, B.T. (2001). Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2, Yant, L.J., Friedrich, T.C., Johnson, R.C., May, G.E., Maness, N.J., Enz, A.M., Lifson, J.D., O Connor, D.H., Carrington, M., and Watkins, D.I. (2006). The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80, Cell 155, , October 24, 2013 ª2013 Elsevier Inc. 539
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys Dan H. Barouch, 1,2, * Kathryn E. Stephenson, 1 Erica N. Borducchi, 1 Kaitlin Smith, 1 Kelly
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationNIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2010 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Nat Med. 2010 March ; 16(3): 319 323. doi:10.1038/nm.2089. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationTreatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques
SUPPORTING INFORMATION FOR: Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques Lia Vassena, 1,2 Huiyi Miao, 1 Raffaello Cimbro,
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationMosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
Mosaic vaccines elicit CD + T lymphocyte responses that fer enhanced immune coverage of diverse HIV strains in monkeys 21 Nature America, Inc. All rights reserved. Sampa Santra 1, Hua-Xin Liao 2, Ruijin
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationA centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys Sampa Santra, Bette T. Korber, Mark Muldoon, Dan H. Barouch, Gary J. Nabel, Feng Gao, Beatrice
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationAntibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
JOURNAL OF VIROLOGY, July 2011, p. 6906 6912 Vol. 85, No. 14 0022-538X/11/$12.00 doi:10.1128/jvi.00326-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Antibody-Dependent Cell-Mediated
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationAIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationHepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce higher T cell
CVI Accepts, published online ahead of print on 5 December 2012 Clin. Vaccine Immunol. doi:10.1128/cvi.00605-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Hepatitis C genotype
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationHIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1- Infected Individuals on Early Initiated Antiretroviral Therapy The Harvard community has made this article openly
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration
V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationEvaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
More informationUnderstanding HIV. Transmitted/Founder Viruses. Brandon Keele SAIC-Frederick National Cancer Institute
Understanding HIV Transmission Utilizing Transmitted/Founder Viruses Brandon Keele SAIC-Frederick National Cancer Institute AIDS Vaccine 2011 15 September 2011 Overview Several years ago, the CHAVI sought
More informationSupporting Information
Supporting Information Walker et al. 1.173/pnas.111753118 - JR-CSF 1 3 1 4 1 5 1 6 1 7 1 8 blank beads protein A beads JR-FL - 1 3 1 4 1 5 1 6 1 7 1 8 - MGRM-C26 1 3 1 4 1 5 1 6 1 7 1 8 reciprocal serum
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationImmunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group
report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Barouch DH, Tomaka FL Wegmann F, et al. Evaluation
More informationPress conference abstracts Vaccine and Antibody Research Monday, 22 October 2018
Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018 OA02.05LB Vaccine-induced Gene Signature Correlates with Protection against Acquisition in Three Independent Vaccine Efficacy
More informationDissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Cell Supplemental Information Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology Amy W. Chung, Manu P. Kumar, Kelly B. Arnold, Wen Han Yu, Matthew K. Schoen, Laura
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationVirus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.
More informationNIH Public Access Author Manuscript Nat Rev Microbiol. Author manuscript; available in PMC 2014 November 19.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Microbiol. 2014 November ; 12(11): 765 771. doi:10.1038/nrmicro3360. Novel vaccine vectors for HIV-1 Dan H. Barouch and Center
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationLack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies
Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies The Harvard community has made this article openly available. Please share how this access
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationTherapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys The MIT Faculty has made this article openly available. Please share how this access benefits
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationWhat is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationIt has been 25 years since HIV-1 was identified as the causative
Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically
More informationImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationIs an HIV Vaccine Possible?
304 BJID 2009; 13 (August) Is an HIV Vaccine Possible? Nancy A. Wilson 1,2 and David I. Watkins 1,2 1 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; 2 Wisconsin National
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationImmunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationHeterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,
More informationFaculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationImmunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239
Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste
More informationArticles. Published online July 6,
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Dan H Barouch*, Frank L Tomaka*,
More informationThe inherent resistance of human immunodeficiency virus type
A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays Michael D.
More informationAd26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV- Infected Rhesus Monkeys
Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV- Infected Rhesus Monkeys The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationRESEARCH ARTICLE Menon et al., Journal of General Virology 2017;98: DOI /jgv
RESEARCH ARTICLE Menon et al., Journal of General Virology 2017;98:2143 2155 DOI 10.1099/jgv.0.000863 DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationChallenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
More informationReceived 9 August 2004/Accepted 26 October 2004
JOURNAL OF VIROLOGY, Mar. 2005, p. 3358 3369 Vol. 79, No. 6 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.6.3358 3369.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Protection
More informationSignificant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen
JOURNAL OF VIROLOGY, June 2011, p. 5764 5772 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.00342-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Significant Protection
More informationADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3*
ADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3* 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, University
More informationCD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection
JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationExploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial
RV RV 144 Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial J Kaewkungwal, P Pitisuttithum, S Nitayapan, D. Stablein,
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationMacaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission Dan H. Barouch a,b,1, Per Johan Klasse c, Jason Dufour d, Ronald S. Veazey d, and John P. Moore c,1 a Beth
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationLow-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys
JOURNAL OF VIROLOGY, Oct. 2010, p. 10406 10412 Vol. 84, No. 19 0022-538X/10/$12.00 doi:10.1128/jvi.01155-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Low-Dose Mucosal Simian
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationDepartment of Surgery, Duke University, Durham, North Carolina; and 7 Southern Research Institute, Frederick, Maryland
MAJOR ARTICLE Highly Attenuated Rabies Virus Based Vaccine Vectors Expressing Simian-Human Immunodeficiency Virus 89.6P Env and Simian Immunodeficiency Virus mac239 Gag Are Safe in Rhesus Macaques and
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More information* Corresponding author: Tel.: ; Fax:
JVI Accepted Manuscript Posted Online 8 February 2017 J. Virol. doi:10.1128/jvi.02182-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
More informationReceived 29 August 2002/Accepted 3 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human
More informationADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV(mac)251 Challenge
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 8-2012 ADCC Develops Over Time during Persistent
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationWhat are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific
14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More information